Notably, treatment of BCC and MB with BET inhibitors JQ1 and I-BET151 was able to suppress the expression of HH pathway target genes even in the presence of resistance mechanisms to SMO inhibitors, such as mutations of SMO or SUFU, or GLI2 amplifications [192,193], thus providing an effective strategy for treating resistant, HH-driven tumors. This evidence concerns the gene GLI2 and skin basal cell carcinoma.